Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880790 | 1.00 | PDK2 (0.42) | PDK2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL22551922 | 0.80 | PLCG1 (0.43) | PDK2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30880760 | 0.80 | PLCG1 (0.43) | PDK2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29399289 | 0.78 | PDK2 (0.39) | PDK2KDM4EALDH1A1AAK1F2 | |
| SCHEMBL24444166 | 0.78 | PDK2 (0.39) | PDK2KDM4EALDH1A1AAK1F2 | |
| SCHEMBL21730330 | 0.78 | HTR7 (0.50) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL26563553 | 0.77 | PDK2 (0.49) | PDK2KDM4EALDH1A1RBP4SMN1; SMN2 | |
| SCHEMBL24553506 | 0.76 | HTR7 (0.57) | PDK2KDM4EALDH1A1RBP4SMN1; SMN2 | |
| SCHEMBL24553509 | 0.76 | PDK2 (0.43) | PDK2ALDH1A1SSTR4GBA1AAK1 | |
| SCHEMBL15058155 | 0.75 | ALDH1A1 (0.51) | PDK2KDM4EALDH1A1RBP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDK2 96/4885CHRM2 289/4885CHRM4 803/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDK2 96/4885CHRM2 289/4885CHRM4 803/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDK2 96/4885CHRM2 289/4885CHRM4 803/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDK2 96/4885CHRM2 289/4885CHRM4 803/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDK2 96/4885CHRM2 289/4885CHRM4 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.